Cyclo Therapeutics Equity Warrants Exp 14th Nov 2025 *W EXP 12/11/2025
Change company Symbol lookup
Select an option...
CYTHW Cyclo Therapeutics Equity Warrants Exp 14th Nov 2025 *W EXP 12/11/2025
FR First Industrial Realty Trust Inc
PNI PIMCO New York Municipal Income Fund II
NIB iPath? Bloomberg Cocoa Subindex Total Return(SM) ETN
DG Dollar General Corp
SPCO Stephan Co
KEX Kirby Corp
GM General Motors Co
F Ford Motor Co
MSFT Microsoft Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Cyclo Therapeutics, Inc. is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. It is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The Company's product lines include Trappsol and Aquaplex. It sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Closing Price
$0.76
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.78
Day's Low
0.5088
Volume
(Above Average)
Volume:
1,592

10-day average volume:
1,592
1,592

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Digital Turbine, Inc. with Losses of $250,000 to Contact the Firm

8:25 am ET June 30, 2022 (Newsfile) Print

Los Angeles, California--(Newsfile Corp. - June 30, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Digital Turbine, Inc. ("Digital Turbine" or "the Company") (NASDAQ: APPS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between August 9, 2021 and May 17, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before August 5, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Digital Turbine's recent acquisitions including AdColony and Fyber are agents in certain product lines. Revenue for these product lines should be reported as not of license fees and revenue share instead of on the basis of gross sales. The Company failed to maintain appropriate internal controls over financial reporting. The Company overstated its net revenues through fiscal year 2022. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Digital Turbine, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

SOURCE:

The Schall Law Firm

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129602

comtex tracking

COMTEX_409477174/2523/2022-06-30T08:25:55

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.